XML 37 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (21,034,643) $ (17,897,137)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 152,573 113,218
Amortization of right-of-use assets 223,030 225,059
Accounts receivable reserves and allowances (59,982) (247,845)
Inventory reserves 18,943 (108,138)
Common stock issued for professional services 101,750
Fair value of warrants issued for professional services 298,651
Stock-based compensation 5,484,044 5,293,651
Fair value of warrant modification for professional services 67,370
Goodwill and fixed asset impairment 4,239,000
Change in fair value of warrant liabilities (906,345) (4,723,187)
Changes in operating assets and liabilities:    
Accounts receivable 417,708 41,250
Inventory and equipment held for lease (637,410) 111,422
Prepaid expenses and other assets (99,251) 1,298,998
Accounts payable (33,397) 385,455
Accrued expenses and other current liabilities (76,266) 1,047,163
R&D grant liability (534,426)
Operating lease liability (134,091) (254,740)
Deferred revenue (62,775) (416,312)
Deferred tax liability (271,622)
Net cash used in operating activities (13,247,540) (14,730,742)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (164,684) (134,471)
Purchases of equipment held for lease (154,433)
Payments for patents and licenses (6,893)
Net cash acquired in business combination 135,354
Net cash used in investing activities (183,763) (141,364)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from warrant exercises 7,173 459,476
Proceeds from issuance of shares and warrants pursuant to Securities Purchase Agreements 8,820,000
Proceeds from issuance of convertible debt - related party 2,903,847
Offering costs of Securities Purchase Agreements (706,929)
Principal payments on notes payable (138,739)
Fractional share payments related to the reverse stock split (505)
Net cash provided by financing activities 2,910,515 8,433,808
Net change in cash and restricted cash (10,520,787) (6,438,298)
Effect of exchange rate changes on cash and restricted cash 22,639
Cash and restricted cash - beginning of period 17,538,272 23,976,570
Cash and restricted cash - end of period 7,040,123 17,538,272
Cash paid during the year for:    
Interest 1,233
Taxes 5,571 5,133
NONCASH FINANCING AND INVESTING ACTIVITIES:    
Issuance of common stock for conversion of preferred stock after closing of reverse recapitalization 243
Right-of-use assets obtained in exchange for operating lease liabilities 1,439,830
Fair value of shares issued for cashless warrant exercises 764,657
Net transfers to inventory from equipment held for lease 1,304
Fair value of warrant modifications pursuant to Securities Purchase Agreements 9,439 2,253,536
Fair value of warrant liabilities on date of exercise 858 1,900,713
Fair value of warrant modifications for business acquisition 33,543
ACQUISITION:    
Fair value of assets acquired (5,896,278)
Fair value of liabilities assumed, net of goodwill 2,321,845
Fair value of Alpha Capital/Qualigen warrants repriced due to acquisition 696
Fair value of Qualigen prefunded warrant issued in exchange for NanoSynex stock 1,804,102
Fair value of Qualigen common stock issued in exchange for NanoSynex stock 1,904,989
Net cash acquired in business combination (Note 3) $ 135,354